Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00811902 |
Recruitment Status :
Completed
First Posted : December 19, 2008
Last Update Posted : February 26, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The primary objective is to assess the activity of nerispirdine in improving the ability to walk, in patients with multiple sclerosis (MS).
Secondary objectives:
- To assess other measures of walking ability, tiredness, and lower limb muscular strength, spasticity, clinical assessment by subject and clinical assessment of change by the Study Investigator
- To assess the safety and tolerance of nerispirdine
- To evaluate the pharmacokinetics (PK) parameters of nerispirdine
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Multiple Sclerosis | Drug: Nerispirdine Drug: placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 405 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients With Multiple Sclerosis. |
Study Start Date : | December 2008 |
Actual Primary Completion Date : | March 2010 |
Actual Study Completion Date : | March 2010 |
Arm | Intervention/treatment |
---|---|
Experimental: Nerispirdine 50mg
Nerispirdine 50mg once daily for 14 weeks
|
Drug: Nerispirdine
tablet, oral administration
Other Name: HP184 |
Experimental: Nerispirdine 100mg
Nerispirdine 100mg once daily for 14 weeks
|
Drug: Nerispirdine
tablet, oral administration
Other Name: HP184 |
Experimental: Nerispirdine 200mg
Nerispirdine 200mg once daily for 14 weeks
|
Drug: Nerispirdine
tablet, oral administration
Other Name: HP184 |
Placebo Comparator: Placebo
Placebo for Nerispirdine once daily for 14 weeks
|
Drug: placebo
tablet, oral administration |
- Responder criterion based on consistency of improved response in walking speed on the Timed 25-Foot Walk (T25-FWT) [ Time Frame: 14 weeks ]
- Change from baseline to endpoint in the 12-item MS Walking Scale (MSWS-12) [ Time Frame: 14 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinically definite MS (according to McDonald criteria),
Exclusion Criteria:
- Multiple sclerosis exacerbation or clinical relapse within 6-month prior to the screening visit.
- Subject who is not able to complete two trials of a timed 25 foot walk, with or without an assisted device,
- Patients without valid V1, V2, and V4 T25-FW measurements are not eligible for randomization.
- Female patients who are either pregnant or breastfeeding.
Other protocol-defined inclusion/exclusion criteria may apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00811902
United States, New Jersey | |
Sanofi-aventis Administrative Office | |
Bridgewater, New Jersey, United States, 08807 | |
Canada | |
Sanofi-aventis Administrative Office | |
Laval, Canada | |
Finland | |
Sanofi-aventis Administrative Office | |
Helsinki, Finland | |
France | |
Sanofi-Aventis Administrative Office | |
Paris, France | |
Germany | |
Sanofi-aventis Administrative Office | |
Berlin, Germany | |
Norway | |
Sanofi-Aventis Administrative Office | |
Lysaker, Norway | |
Spain | |
Sanofi-aventis Administrative Office | |
Barcelona, Spain |
Study Director: | Clinical Sciences & Operations | Sanofi |
Responsible Party: | Sanofi |
ClinicalTrials.gov Identifier: | NCT00811902 |
Other Study ID Numbers: |
DRI10566 2008-001999-67 ( EudraCT Number ) |
First Posted: | December 19, 2008 Key Record Dates |
Last Update Posted: | February 26, 2016 |
Last Verified: | January 2016 |
Multiple sclerosis |
Multiple Sclerosis Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System |
Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases |